Drug updated on 11/17/2023
|Tablet (oral; 200 mg, 550 mg)
| Ongoing and
- Indicated for treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older.
- Indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
- Indicated for treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Product Monograph / Prescribing Information
|Efficacy of rifaximin in patients with abdominal bloating or distension a systematic review and meta-analysis.
|Journal of Clinical Gastroenterology
|Role of rifaximin in the management of alcohol-associated hepatitis: a systematic review and meta-analysis.
|Journal of Gastroenterology and Hepatology
|Xifaxan (rifaximin) Prescribing Information.
|Salix Pharmaceuticals, Bridgewater, NJ
|The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of left-sided colonic diverticulitis.
|Diseases of the Colon and Rectum
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|ACG clinical guideline: management of irritable bowel syndrome
|The American Journal of Gastroenterology